Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

NCT07022834 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Langerhans Cell Histiocytosis (LCH)

Interventions

DRUG: Dabrafenib or Trametinib and Clofarabine

Sponsor

West China Second University Hospital